Gavi, the Vaccine Alliance

Subterms

    Latest story

    113 Shares159 Views

    Trump Budget Eliminates Funding for Crucial Global Vaccination Programs

    by

    The spending proposal terminates support of health programs that, according to the proposal, “do not make Americans safer.”The Trump administration’s proposed budget for the coming fiscal year eliminates funding for programs that provide lifesaving vaccines around the world, including immunizations for polio.The budget, submitted to Congress last week, proposes to eliminate the Centers for Disease Control and Prevention’s global health unit, effectively shutting down its $230 million immunization program: $180 million for polio eradication and the rest for measles and other vaccine-preventable diseases. The budget plan also withdraws financial support for Gavi, the international vaccine alliance that purchases vaccines for children in developing countries.Overall, the budget request explicitly follows President Trump’s America First policy, slashing funds for global health programs that fight H.I.V. and malaria, and cutting support altogether to fight diseases that affect only poorer countries.“The request eliminates funding for programs that do not make Americans safer, such as family planning and reproductive health, neglected tropical diseases, and nonemergency nutrition,” the proposal said.Many public health experts said that such thinking is flawed because infectious diseases routinely breach borders. The United States is battling multiple measles outbreaks, prompting the C.D.C. last week to warn travelers about the risks of contracting measles. Each of those outbreaks began with a case of measles contracted by an international traveler.“Every single measles case this year is related to actual importations of the virus into the United States,” said Dr. Walter Orenstein, associate director of the Emory Vaccine Center and a former director of the United States’ Immunization Program.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    More stories

    • 100 Shares119 Views

      in Elections

      U.S. to End Vaccine Funds for Poor Countries

      by

      A 281-page spreadsheet obtained by The Times lists the Trump administration’s plans for thousands of foreign aid programs.The Trump administration intends to terminate the United States’ financial support for Gavi, the organization that has helped purchase critical vaccines for children in developing countries, saving millions of lives over the past quarter century, and to significantly scale back support for efforts to combat malaria, one of the biggest killers globally.The administration has decided to continue some key grants for medications to treat H.I.V. and tuberculosis, and food aid to countries facing civil wars and natural disasters.Those decisions are included in a 281-page spreadsheet that the United States Agency for International Development sent to Congress Monday night, listing the foreign aid projects it plans to continue and to terminate. The New York Times obtained a copy of the spreadsheet and other documents describing the plans.The documents provide a sweeping overview of the extraordinary scale of the administration’s retreat from a half-century-long effort to present the United States to the developing world as a compassionate ally and to lead the fight against infectious diseases that kill millions of people annually.The cover letter details the skeletal remains of U.S.A.I.D. after the cuts, with most of its funding eliminated, and only 869 of more than 6,000 employees still on active duty.In all, the administration has decided to continue 898 U.S.A.I.D. awards and to end 5,341, the letter says. It says the remaining programs are worth up to $78 billion. But only $8.3 billion of that is unobligated funds — money still available to disburse. Because that amount covers awards that run several years into the future, the figure suggests a massive reduction in the $40 billion that U.S.A.I.D. used to spend annually.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

    • 125 Shares189 Views

      in Elections

      W.H.O. Authorizes Mpox Vaccine, Clearing Way for Use in Africa

      by

      The decision is a crucial step in getting shots to the Democratic Republic of Congo, the center of the outbreak.The World Health Organization has given its authorization to a first vaccine to protect against mpox, a decision announced in such haste on Friday that it caught even the head of the company that makes the vaccine by surprise.The vaccine, made by the Danish company Bavarian Nordic, has been approved by the regulatory authorities in Europe as well as the United States and other high-income countries since a global mpox outbreak in 2022. But low- and middle-income countries rely on the W.H.O., through a process called prequalification, to determine which drugs, vaccines and health technologies are safe and efficient uses of limited health funding, and the organization had declined to act until now.The W.H.O. had come under increasing criticism for declaring a global public health emergency for mpox last month without giving a vaccine that prequalification stamp of approval, or a more provisional form of approval called emergency use authorization. Bavarian Nordic first submitted its safety and effectiveness data on the vaccine, called Jynneos, to the W.H.O. in 2023. The W.H.O. had defended its slow pace of review, saying that it needed to subject the vaccine to careful study because it, and two others that have been used to protect against mpox, were originally designed as smallpox immunizations, and because delivering it in low-resource settings such as Central Africa would involve factors different from those relating to its use in high-income countries.But on Friday morning, the W.H.O. suddenly said it was authorizing the shot.“This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future,” Dr. Tedros Adhanom Ghebreyesus, the W.H.O. director general, said in a statement.Paul Chaplin, Bavarian Nordic’s chief executive, said he was among the many who had been caught off guard.“We’ve got there eventually — I don’t know quite how,” he said. “But it’s good news. It’s going to make the regulatory pathway much easier.”We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More